Reactive arthritis

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 6, 2006, Pages 1119-1137

  Rihl, Markus ^a   Klos, Andreas ^a   Köhler, Lars ^b   Kuipers, Jens G ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Rheumatologische Facharztpraxis   (Germany)

^c Rotes Kreuz Krankenhaus   (Germany)

Author keywords

HLA B27; persistence; reactive arthritis; spondyloarthritis; urogenital gastrointestinal respiratory infection

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; AZITHROMYCIN; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CIPROFLOXACIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOXYCYCLINE; GLUCOCORTICOID; HLA B27 ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMECYCLINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ANTIBODY; ANTIINFECTIVE AGENT; ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; ARTHRITIS; BACTERIAL INFECTION; BACTERIUM IDENTIFICATION; BORRELIA; BRUCELLA; CAMPYLOBACTER; CHLAMYDIA; CLINICAL FEATURE; CLINICAL TRIAL; CLOSTRIDIUM; CONJUNCTIVITIS; DISEASE COURSE; DRUG EFFICACY; ENTHESITIS; ENTHESOPATHY; ERYTHEMA NODOSUM; FALSE NEGATIVE RESULT; GASTROINTESTINAL INFECTION; HAEMOPHILUS; HAFNIA; HOST CELL; HUMAN; HYPOTHESIS; IMMUNE SYSTEM; JOINT SURGERY; KERATODERMA; LEPTOSPIRA; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MYCOBACTERIUM; NEISSERIA; ORTHOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REACTIVE ARTHRITIS; RESPIRATORY TRACT INFECTION; REVIEW; SALMONELLA; SENSITIVITY AND SPECIFICITY; SEROLOGY; SHIGELLA; STAPHYLOCOCCUS; STREPTOCOCCUS; SYMPTOM; UREAPLASMA; URETHRITIS; UROGENITAL TRACT INFECTION; VIBRIO; YERSINIA; CHLAMYDIASIS; IMMUNOLOGY; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, REACTIVE; CHLAMYDIA INFECTIONS; HLA-B27 ANTIGEN; HUMANS;

EID: 33751194865     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.08.008     Document Type: Review

References (90)

1. Reiter H. Über eine bisher unbekannte Spirochäteninfektion (Spirochaetosis arthritica). Deutsche Medizinische Wochenschrift 42 (1916) 1535-1536
2. Ahvonen P., Sievers K., and Aho K. Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatologica Scandinavica 15 (1969) 232-253
3. Aho K., Ahvonen P., Lassus A., et al. HL-A antigen 27 and reactive arthritis. Lancet 2 (1973) 157-161
4. Kvien T.K., Glennas A., Melby G., et al. Reactive arthritis: incidence, triggering agents and clinical presentation. The Journal of Rheumatology 21 (1994) 115-122
5. Toivanen A., and Toivanen P. Reactive arthritis. Best Practice and Research Clinical Rheumatology 18 (2004) 689-703
6. Gaston J.S.H., and Lillicrap M.S. Arthritis associated with enteric infection. Best Practice and Research Clinical Rheumatology 17 (2003) 219-239
7. Zeidler H., Kuipers J., and Köhler L. Chlamydia-induced arthritis. Current Opinion in Rheumatology 16 (2004) 380-392
8. Yu D., and Kuipers J.G. Role of bacteria and HLA-B27 in the pathogenesis of reactive arthritis. Rheumatic Diseases Clinics of North America 29 (2003) 21-36
9. Leirisalo M., Skylv G., Kousa M., et al. Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis and Rheumatism 25 (1982) 249-259
10. Hogan R.J., Mathews S.A., Mukhopadhyay S., et al. Chlamydial persistence: beyond the biphasic paradigm. Infection and Immunity 72 (2004) 1843-1855
11. Kuipers J.G., Zeidler H., and Köhler L. How does Chlamydia cause arthritis?. Rheumatic Diseases Clinics of North America 29 (2003) 613-629
12. Granfors K., Merilahti-Palo R., Luukkainen R., et al. Persistence of yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis and Rheumatism 41 (1998) 855-862
13. Cox C.J., Kempsell K.E., and Gaston J.S.H. Investigation of infectious agents associated with arthritis by reverse transcription PCR of bacterial rRNA. Arthritis Research and Therapy 5 (2003) R1-R8 [Epub 2002 Oct 11]
14. Nanagara R., Li F., Beutler A., et al. Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Arthritis and Rheumatism 38 (1995) 1410-1417
15. Gerard H.C., Branigan P.J., Schumacher H.R., and Hudson A.P. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. The Journal of Rheumatology 25 (1998) 734-742
16. Gerard H.C., Whittum-Hudson J.A., Schumacher H.R., and Hudson A.P. Synovial Chlamydia trachomatis up-regulates expression of a panel of genes similar to that transcribed by Mycobacterium tuberculosis during persistent infection. Annals of the Rheumatic Diseases 65 (2006) 321-327
17. Clements M.O., Eriksson S., Thompson A., et al. Polynucleotide phosphorylase is a global regulator of virulence and persistency in Salmonella enterica. Proceedings of the National Academy of Sciences U S A 99 (2002) 8784-8789
18. Bohn E., Müller S., Lauber J., et al. Gene expression patterns of epithelial cells modulated by pathogenicity factors of Yersinia enterocolitica. Cellular Microbiology 6 (2003) 129-141
19. Sassetti C.M., and Rubin E.J. Genetic requirements for mycobacterial survival during infection. Proceedings of the National Academy of Sciences U S A 100 (2003) 12989-12994
20. Da Costa C.U., Wantia N., Kirschning C.J., et al. Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo. European Journal of Immunology 34 (2004) 2874-2884
21. Darville T., O'Neill J.M., Andrews C.W., et al. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. Journal of Immunology 171 (2003) 6187-6197
22. Hess S., Rheinheimer C., Tidow F., et al. The reprogrammed host: Chlamydia trachomatis-induced up-regulation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes. Arthritis and Rheumatism 44 (2001) 2392-2401
23. Hess S., Peters J., Bartling G., et al. More than just innate immunity: comparative analysis of Chlamydophila pneumoniae and Chlamydia trachomatis effects on host-cell gene regulation. Cellular Microbiology 5 (2003) 785-795
24. Yamamoto T., Sashinami H., Takaya A., et al. Disruption of the Genes for ClpXP Protease of Salmonella enterica serovar typhimurium results in persistent infection in mice, and development of persistence requires endogenous gamma interferon and tumor necrosis factor alpha. Infection and Immunity 69 (2001) 3164-3174
25. Hoffmann R., van Erp K., Trülzsch K., and Heesemann J. Transcriptional responses of murine macrophages to infection with Yersinia enterocolitica. Cellular Microbiology 6 (2003) 377-390
26. Fan T., Lu H., Hu H., et al. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. The Journal of Experimental Medicine 187 (1998) 487-496
27. Fischer S.F., Vier J., Kirschnek S., et al. Chlamydia inhibit host cell apoptosis by degradation of proapoptotic BH3-only proteins. The Journal of Experimental Medicine 200 (2004) 905-916
28. Zhong G., Fan P., Ji H., et al. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. The Journal of Experimental Medicine 193 (2001) 935-942
29. Gaston J.S., Deane K.H., Jecock R.M., and Pearce J.H. Identification of 2 Chlamydia trachomatis antigens recognized by synovial fluid T cells from patients with Chlamydia induced reactive arthritis. The Journal of Rheumatology 23 (1996) 130-136
30. Matyszak M.K., Young J.L., and Gaston J.S. Uptake and processing of Chlamydia trachomatis by human dendritic cells. European Journal of Immunology 32 (2002) 742-751
31. Mertz A.K., Ugrinovic S., Lauster R., et al. Characterization of the synovial T cell response to various recombinant Yersinia antigens in Yersinia enterocolitica-triggered reactive arthritis. Heat-shock protein 60 drives a major immune response. Arthritis and Rheumatism 41 (1998) 315-326
32. Baeten D., Van Damme N., Van den Bosch F., et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases 60 (2001) 750-755
33. Zou J., Rudwaleit M., Brandt J., et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis and Rheumatism 48 (2003) 780-790
34. Baeten D., Vandooren B., De Rycke L., et al. Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. Arthritis and Rheumatism 50 (2004) 1015-1016
35. Yin Z., Braun J., Neure L., et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis and Rheumatism 40 (1997) 1788-1797
36. Schlaak J., Hermann E., Ringhoffer M., et al. Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. European Journal of Immunology 22 (1992) 2771-2776
37. Lahesmaa R., Yssel H., Batsford S., et al. Yersinia enterocolitica activates a T helper type 1-like T cell subset in reactive arthritis. Journal of Immunology 148 (1992) 3079-3085
38. Simon A.K., Seipelt E., Wu P., et al. Analysis of cytokine profiles in synovial T cell clones from chlamydial reactive arthritis patients: predominance of the Th1 subset. Clinical and Experimental Immunology 94 (1993) 122-126
39. Rihl M., Gu J., Baeten D., et al. Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor alpha and interferon gamma. Annals of the Rheumatic Diseases 63 (2004) 1673-1676
40. Hermann E., Yu D.T., Meyer zum Buschenfelde K.H., and Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet 342 (1993) 646-650
41. Duchmann R., May E., Ackermann B., et al. HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self-antigens are dominated by closely related TCRBV gene segments. A study in patients with reactive arthritis. Scandinavian Journal of Immunology 43 (1996) 101-108
42. Dulphy N., Peyrat M.A., Tieng V., et al. Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. Journal of Immunology 162 (1999) 3830-3839
43. Kapasi K., and Inman R.D. HLA-B27 expression modulates gram-negative bacterial invasion into transfected L cells. Journal of Immunology 148 (1992) 3554-3559
44. Ortiz-Alvarez O., Yu D.T., Petty R.E., and Finlay B.B. HLA-B27 does not affect invasion of arthritogenic bacteria into human cells. Journal of Rheumatology 25 (1998) 1765-1771
45. Laitio P., Virtala M., Salmi M., et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. European Journal of Immunology 27 (1997) 1331-1338
46. Taurog J.D., Maika S.D., Satumtira N., et al. Inflammatory disease in HLA-B27 transgenic rats. Immunological Reviews 169 (1999) 209-223
47. Khare S.D., Hansen J., Luthra H.S., and David C.S. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. The Journal of Clinical Investigation 98 (1996) 2746-2755
48. Mear J.P., Schreiber K.L., Munz C., et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. Journal of Immunology 163 (1999) 6665-6670
49. Popov I., Dela Cruz C.S., Barber B.H., et al. The effect of an anti-HLA-B27 immune response on CTL recognition of Chlamydia. Journal of Immunology 167 (2001) 3375-3382
50. Popov I., Dela Cruz C.S., Barber B.H., et al. Breakdown of CTL tolerance to self HLA-B*2705 induced by exposure to Chlamydia trachomatis. Journal of Immunology 169 (2002) 4033-4038
51. Colbert R.A. HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum?. Molecular Medicine Today 6 (2000) 224-230
52. Turner M.J., Sowders D.P., DeLay M.L., et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. Journal of Immunology 175 (2005) 2438-2448
53. Laivoranta S., Ilonen J., Tuokko J., et al. HLA frequencies in HLA-B27 negative patients with reactive arthritis. Clinical and Experimental Rheumatology 13 (1995) 637-640
54. Marker-Hermann E., and Hohler T. Pathogenesis of human leukocyte antigen B27-positive arthritis. Information from clinical materials. Rheumatic Diseases Clinics of North America 24 (1998) 865-881
55. Braun J., Yin Z., Spiller I., et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis and Rheumatism 42 (1999) 2039-2044
56. Kaluza W., Leirisalo-Repo M., Marker-Hermann E., et al. IL10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients. Arthritis and Rheumatism 44 (2001) 1209-1214
57. Wang C., Tang J., Geisler W.M., et al. Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlamydia trachomatis infection in high-risk adolescents. The Journal of Infectious Diseases 191 (2005) 1084-1092
58. Inman R.D. Classification criteria for reactive arthritis. The Journal of Rheumatology 26 (1999) 1219-1220
59. Sieper J., and Braun J. Problems and advances in the diagnosis of reactive arthritis. The Journal of Rheumatology 26 (1999) 1222-1223
60. Kuipers J.G., Wollenhaupt J., Klos A., and Zeidler H. Critical appraisal of molecular biological techniques for detecting bacteria in synovial specimens. Revue du Rhumatisme 66 supplement (1999) 3S-8S
61. Flores D., Marquez J., Garza M., and Espinoza L.R. Reactive arthritis: newer developments. Rheumatic Diseases Clinics of North America 29 (2003) 37-59
62. Sieper J., Rudwaleit M., Braun J., and van der Heijde D. Diagnosing reactive arthritis Role of clinical setting in the value of serologic and microbiologic assays. Arthritis and Rheumatism 46 (2002) 319-327
63. Haibel H., Rudwaleit M., Sieper J., et al. Diagnostik der reaktiven Arthritis. Zeitschrift für Rheumatologie 63 (2004) 211-215
64. Bardin T., Enel C., Cornelis F., et al. Antibiotic treatment of veneraeal disease and Reiter's syndrome in a Greenland population. Arthritis and Rheumatism 35 (1992) 190-194
65. Adimora A.A. Treatment of uncomplicated genital Chlamydia trachomatis infection in adults. Clinical Infectious Diseases 35 supplement 2 (2002) S183-S186
66. Colemegna I., Cuchacovich R., and Espinoza L.R. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clinical Microbiology Reviews 17 (2004) 348-369
67. Köhler L., Kuipers J.G., and Zeidler H. Persistent chlamydial infections. Biomedical Progress 15 (2002) 28-34
68. Dreses-Werringloer U., Padubrin I., Zeidler H., and Köhler L. Effect of azithromycin and rifampin on the infection of Chlamydia trachomatis in vitro. Antimicrobial Agents Chemotheraphy 45 (2001) 3001-3008
69. Carter J.D., Valeriano J., and Vasey F.B. Doxycyclin versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison. Journal of Rheumatology 31 (2004) 1973-1980
70. Pavlica L., Nikolic D., Magic Z., et al. Successful treatment of postvenereal reactive arthritis with synovectomy and 3 months azithromycin. Journal of Clinical Rheumatology 11 (2005) 257-263
71. Laasila K., Laasonen L., and Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Annals of the Rheumatic Diseases 62 (2003) 655-658
72. Yli-Kerttula T., Luukkainen R., Yli-Kerttula U., et al. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Annals of the Rheumatic Diseases 62 (2003) 880-884
73. Leirisalo-Repo. Reactive Arthritis. Scandinavian Journal of Rheumatology 34 (2005) 251-259
74. Koehler L., Kuipers J.G., and Zeidler H. Managing seronegative spondarthritides. Rheumatology 39 (2000) 360-368
75. Reveille J.D., and Arnett C. Spondyloarthritis: update on pathogensis and management. The American Journal of Medicine 118 (2005) 592-603
76. Anandarajah A., and Ritchlin C.T. Treatment update on spondyloarthropathy. Current Opinion in Rheumatology 17 (2005) 247-256
77. Clegg D.O., Reda D.J., Weisman M.H., et al. Henderson: Comparison of sulphasalzine and placebo in the treatment of reactive arthritis. Arthritis and Rheumatism 39 (1996) 2021-2027
78. Braun J., and Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology 4 (2004) 1072-1084
79. Meador R., Hsia E., Kitumnuaypong T., and Schumacher H.R. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clinical and Experimental Rheumatology 20 6 supplement 28 (2002) S130-S134
80. Kaipiainen-Seppänen O., Niinisalo H., Korpilähde T., and Virolainen J. Treatment of reactive arthritis with infliximab. Scandinavian Journal of Rheumatology 32 (2003) 122-124
81. Flagg S.D., Meador R., Hsia E., Kitumnuaypong T., and Schumacher H.R. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Care and Research 53 (2005) 613-617
82. Braun J., Davis J., Dougados M., et al. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 65 (2006) 316-320 [Epub 2005 Aug 11]
83. Lauhio A., Leirisalo-Repo M., Lähdevirta J., et al. Double-blind, placebo-controlled study of three month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis and Rheumatism 34 (1991) 6-14
84. Putschky N, Pott HG, Kuipers JG et al. A prospective, double-blind trial comparing ten-day versus four-month doxycycline in treatment of Chlamydia-induced reactive arthritis. Annals of the Rheumatic Diseases [in press].
85. Smieja M., MacPherson D.W., Kean W., et al. Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Annals of the Rheumatic Diseases 60 (2001) 1088-1094
86. Sieper J., Fendler C., Laitko S., et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis and Rheumatism 42 (1999) 1386-1396
87. Toivanen A., Yli-Kertulla T., Luukkainen R., et al. Effect of antimicrobial treatment on chronic reactive arthritis. Clinical and Experimental Rheumatology 11 (1993) 301-307
88. Wakefield D., McCluskey P., Verma M., et al. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis and Rheumatism 42 (1999) 1894-1897
89. Yli-Kerttula T., Luukkainen R., Yli-Kerttula U., et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Annals of the Rheumatic Diseases 59 (2000) 565-570
90. Kvien T.K., Gaston J.S.H., Bardin T., et al. Three-month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Annals of the Rheumatic Diseases 63 (2004) 1113-1119